Loading...

KRYS KRYSTAL BIOTECH INC Product Launches 8-K Filing

KRYS

KRYS

KRYSTAL BIOTECH INC

(KRYS)

2025 8-K

Show Summary

Show Summary

Product Expansion

Clinical Trials

Financial Statements

Clinical Trials

New Product Launches

Financial Results

Clinical Results

Clinical Update

Financial Results

Positive Clinical Results

Financial Results Announcement

Annual Meeting of Stockholders

Presentation at ARVO Meeting

Financial Results Announcement

Financial Results Announcement

Earnings Reports

Resignation of Officer

Financial Results Announcement

Expansion in Oncology Pipeline

Securities Purchase Agreement

FDA Approval and Investor C...

Presentation of Data on Top...

Sales Agreement with Cowen ...

Financial Results Announcement

Data Presentation

Appointment of Director

Financial Results Announcement

FDA Review Period Extended

External Links:

On April 28, 2025, Krystal Biotech, Inc. announced that the European Commission approved their treatment VYJUVEK® for Dystrophic Epidermolysis Bullosa.

AI Assistant

KRYSTAL BIOTECH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.